MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, as its Vice President, Non-Clinical and Translational Studies. In her new role, Dr. Chinnasamy will oversee all non-clinical and translational activities for MaxCyte’s CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte’s clinical-stage therapeutic development.
{iframe}https://www.prnewswire.com/news-releases/maxcyte-adds-vice-president-non-clinical-and-translational-studies-to-support-advancement-of-programs-from-its-carma-platform-300888579.html?tc=eml_cleartime{/iframe}